| Name | calcitonin gene related peptide |
|---|---|
| Synonyms | Alpha type CGRP; CT; CGRP; CALC 1; CALC1; CALCA; CGRP 1; CGRP I… |
| Name | sodium fluoride |
|---|---|
| CAS | sodium fluoride (NaF) |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 9881322 | Netelenbos C: Osteoporosis: intervention options. Maturitas. 1998 Nov 16;30(3):235-9. The inhibitors of bone resorption, which include the vitamin Ds, bisphosphonates, calcitonins and gonadal steroids have been variously shown to prevent bone loss or to reduce fractures. At this moment sodium fluoride is not the first choice in treatment of osteoporosis in general practice. |
1(0,0,0,1) | Details |
| 11238469 | Rosen CJ, Bilezikian JP: Clinical review 123: Anabolic therapy for osteoporosis. . J Clin Endocrinol Metab. 2001 Mar;86(3):957-64. By acting at this site in the bone remodeling cycle, estrogens, selective estrogen receptor modulators, calcitonin, and the bisphosphonates all have the capacity to increase bone mineral density and to reduce the risk of new fractures. |
1(0,0,0,1) | Details |
| 9217558 | Deal CL: Osteoporosis: prevention, diagnosis, and management. 136-7 calcitonin, and bisphosphonates have all been proved effective in retarding postmenopausal bone loss and therefore reducing the risk of fracture. The use of sodium fluoride is more controversial, although a recent study has suggested a possible role for slow-release combined with high-dose supplementation. |
1(0,0,0,1) | Details |
| 8600659 | Fojtik Z, Mayer J: [Osteoporosis. 2] . Vnitr Lek. 1995 Dec;41(12):851-7. Further antiresorptive drugs include oral calcitonin, bisphosphonates. Intermittent slow-release sodium fluoride administered for osteoporotic patients inhibits new vertebral fractures, increases the mean spinal bone mass and is safe to use. |
1(0,0,0,1) | Details |
| 10677797 | Blank RD, Bockman RS: A review of clinical trials of therapies for osteoporosis using fracture as an end point. Am J Med. 1997 Jan 27;102(1A):35S-39S. Fracture outcomes have been reported in clinical trials with supplementation, supplementation, replacement therapy (ERT), calcitonin, etidronate, (NaF), parathyroid hormone (PTH), and raloxifene. |
1(0,0,0,1) | Details |
| 12589304 | Davidson MR: Pharmacotherapeutics for osteoporosis prevention and treatment. J Midwifery Womens Health. 2003 Jan-Feb;48(1):39-52. The following effective treatment options for women who have been diagnosed with the disease are discussed: bisphosphonates, calcitonin, and selective estrogen receptor modulators (SERMs). |
1(0,0,0,1) | Details |
| 17898545 | Ross GR, Yallampalli U, Yallampalli C: Cyclic AMP-independent CGRP8-37-sensitive receptors mediate adrenomedullin-induced decrease of CaCl2-contraction in pregnant rat mesenteric artery. J Vasc Res. 2008;45(1):33-44. Epub 2007 Sep 26. Interestingly, sodium fluoride, a nonspecific protein phosphatase inhibitor, completely blocked the effect of adrenomedullin on CaCl (2)-induced contraction. |
0(0,0,0,0) | Details |
| 12530170 | Dimai HP, Pietschmann P, Resch H, Leb G, Klaushofer K: [Guidelines for drug therapy of postmenopausal osteoporosis] . Wien Med Wochenschr. 2002;152(23-24):596-612. In Austria, several pharmacologic options for treatment of osteoporosis are available, including bisphosphonates etidronate, risedronate), selective estrogen receptor modulators (raloxifene), calcitonins (salm-calcitonin, elcatonin), fluorides (sodium-fluoride, monofluorophosphate), anabolic steroids steroid derivates (tibolone), and hormone replacement therapy. |
7(0,0,1,2) | Details |
| 9689207 | Miller P, Lukert B, Broy S, Civitelli R, Fleischmann R, Gagel R, Khosla S, Lucas M, Maricic M, Pacifici R, Recker R, Sarran HS, Short B, Short MJ: Management of postmenopausal osteoporosis for primary care. 141-2. RESULTS: Prevention and treatment are discussed, including hormone replacement therapy and use of calcitonin, sodium fluoride, bisphosphonates, and serum estrogen receptor modulators. |
6(0,0,1,1) | Details |
| 9069161 | Farrerons J, Rodriguez de la Serna A, Guanabens N, Armadans L, Lopez-Navidad A, Yoldi B, Renau A, Vaque J: Sodium fluoride treatment is a major protector against vertebral and nonvertebral fractures when compared with other common treatments of osteoporosis: a longitudinal, observational study. Calcif Tissue Int. 1997 Mar;60(3):250-4. In a 5-year observational study we have compared sodium fluoride (NaF) with different treatments commonly used in the treatment of osteoporosis: estrogens, androgens, and calcitonin, referred to as non-NaF. |
6(0,0,1,1) | Details |
| 18360603 | Maclaughlin EJ, Sleeper RB, McNatty D, Raehl CL: Management of age-related osteoporosis and prevention of associated fractures. Ther Clin Risk Manag. 2006 Sep;2(3):281-95. Drugs which have been shown to decrease the risk of age-related osteoporotic fractures include oral bisphosphonates ibandronate, and risedronate), intranasal calcitonin, estrogen receptor stimulators (eg, selective estrogen receptor modulators [raloxifene]), parathyroid hormone (teriparatide), sodium fluoride, and ranelate. |
6(0,0,1,1) | Details |
| 9673863 | Castelo-Branco C: Management of osteoporosis. Drugs Aging. 1998;12 Suppl 1:25-32. Other widely used treatments for osteoporosis that have been utilised to prevent bone loss include calcitonin and bisphosphonates, supplementation, ossein-hydroxyapatite compound, analogues, sodium fluoride, parathyroid hormone, anabolic steroids and growth hormone. |
6(0,0,1,1) | Details |
| 8990754 | Haines ST, Caceres B, Yancey L: Alternatives to replacement therapy for preventing osteoporosis. . Menopause. 1998 Summer;5(2):123-31. Several drugs-including sex hormones, bisphosphonates, calcitonin, and sodium fluoride-can arrest the progression of osteoporosis and prevent fractures. |
6(0,0,1,1) | Details |
| 14713283 | Pepene CE, Seck T, Diel I, Minne HW, Ziegler R, Pfeilschifter J: Influence of fluor salts, hormone replacement therapy and calcitonin on the concentration of insulin-like growth factor (IGF)-I, IGF-II and transforming growth factor-beta 1 in human iliac crest bone matrix from patients with primary osteoporosis. Eur J Endocrinol. 2004 Jan;150(1):81-91. |
3(0,0,0,3) | Details |
| 9008693 | Isenbarger DW, Chapin BL: Osteoporosis. Postgrad Med. 1997 Jan;101(1):129-32 Therapy with or calcitonin (Calcimar, Miacalcin) is clearly indicated in women with established osteoporosis and may be appropriate for early postmenopausal women with osteopenia. Slow-release sodium fluoride, although still considered experimental, may eventually be given for vertebral fracture in patients with mild to moderate disease. |
2(0,0,0,2) | Details |
| 10847516 | Dobbs MB, Buckwalter J, Saltzman C: Osteoporosis: the increasing role of the orthopaedist. Iowa Orthop J. 1999;19:43-52. If the bone mass is 2.5 SDs below normal peak or if there is an increase in resorption, use of either bisphosphontes, or calcitonin may be appropriate. If there is evidence of low-turnover osteoporosis with decreased osteoblast formation, sodium fluoride should be considered. |
2(0,0,0,2) | Details |
| 10890269 | Krappweis J, Rentsch A, Schwarz UI, Krobot KJ, Kirch W: Outpatient costs of osteoporosis in a national health insurance population. Clin Ther. 1999 Nov;21(11):2001-14. Patients received 106 defined daily doses of osteoporosis medications during the year; 37.0% of the prescribed daily doses were for fluorophosphate/ combinations, 4.3% were for sodium fluoride, and 7.7% were for alone. Sex hormones and calcitonin each accounted for 7.7% of the prescribed daily doses. |
1(0,0,0,1) | Details |